申请人:Glaxo Wellcome Inc.
公开号:US05589474A1
公开(公告)日:1996-12-31
Compounds of formula (I) wherein n is 0, 1 or 2; and R.sup.1 and R.sup.2, which may be the same or different, each represent one or more ring substituent(s) selected from: hydroxy, halogen, cyano, nitro, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl or C.sub.1-6 alkoxy (where the alkyl or cycloalkyl moiety may be optionally substituted by one or more substituents selected from halogen atoms and hydroxyl groups); --NR.sup.4 R.sup.5 where R.sup.4 and R.sup.5 which may be the same or different, each represent hydrogen or C.sub.1-6 are each as defined above; phenyl, phenyl C.sub.1-3 alkoxy or phenyl C.sub.1-3 alkyl where the phenyl group may be optionally substituted by one or more substituents independently selected from C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, nitro, halogen and amino; and --CO.sub.2 H or --COR.sup.7 where R.sup.7 is C.sub.1-6 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is hydrogen or C.sub.1-4 alkyl: and esters, salts and other physiologically functional derivatives thereof, show activity as antiviral agents, for example against HIV. The majority of the compounds are novel.
化合物的公式(I),其中n为0、1或2;R.sup.1和R.sup.2,可以相同或不同,每个都代表一种或多种环取代基,包括:羟基、卤素、氰基、硝基、C.sub.1-6烷基、C.sub.3-6环烷基或C.sub.1-6烷氧基(其中烷基或环烷基部分可以选择性地被一个或多个取代基所取代,所述取代基选择自卤素原子和羟基);--NR.sup.4 R.sup.5,其中R.sup.4和R.sup.5可以相同或不同,每个都代表氢或C.sub.1-6,如上所定义;苯基、苯基C.sub.1-3烷氧基或苯基C.sub.1-3烷基,其中苯基部分可以选择性地被一个或多个取代基所取代,所述取代基独立地选择自C.sub.1-6烷基、C.sub.1-6烷氧基、羟基、硝基、卤素和氨基;以及--CO.sub.2 H或--COR.sup.7,其中R.sup.7为C.sub.1-6烷基或C.sub.3-6环烷基;R.sup.3为氢或C.sub.1-4烷基:以及其酯、盐和其他生理活性衍生物,显示出抗病毒活性,例如对HIV。其中大部分化合物是新的。